Axonics, Inc. (NASDAQ:AXNX) Receives $70.73 Average Target Price from Analysts

Axonics, Inc. (NASDAQ:AXNX - Get Free Report) has earned a consensus recommendation of "Hold" from the thirteen brokerages that are presently covering the company, Marketbeat reports. Eight research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $70.73.

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company restated an "equal weight" rating and set a $71.00 price target (up from $68.00) on shares of Axonics in a research report on Wednesday, January 10th. CL King reaffirmed a "neutral" rating on shares of Axonics in a report on Friday, January 12th. SVB Leerink reiterated a "market perform" rating and set a $71.00 price objective on shares of Axonics in a research report on Friday, January 12th. Needham & Company LLC restated a "hold" rating on shares of Axonics in a report on Wednesday, January 17th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $71.00 target price (down from $75.00) on shares of Axonics in a research note on Friday, January 12th.

Insider Activity at Axonics

In other Axonics news, CFO Kari Leigh Keese sold 3,489 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $236,344.86. Following the completion of the transaction, the chief financial officer now owns 43,323 shares of the company's stock, valued at $2,934,700.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Axonics news, EVP John Woock sold 15,899 shares of the business's stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $1,076,998.26. Following the sale, the executive vice president now owns 77,403 shares of the company's stock, valued at $5,243,279.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kari Leigh Keese sold 3,489 shares of the company's stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $236,344.86. Following the transaction, the chief financial officer now owns 43,323 shares in the company, valued at $2,934,700.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,837 shares of company stock worth $4,459,798. Company insiders own 1.85% of the company's stock.

Institutional Investors Weigh In On Axonics

Several institutional investors and hedge funds have recently modified their holdings of the company. Exchange Traded Concepts LLC purchased a new stake in Axonics during the 3rd quarter worth approximately $37,000. NBC Securities Inc. increased its position in shares of Axonics by 106.4% during the fourth quarter. NBC Securities Inc. now owns 673 shares of the company's stock worth $41,000 after acquiring an additional 347 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Axonics in the fourth quarter valued at $53,000. RiverPark Advisors LLC acquired a new stake in shares of Axonics in the third quarter valued at $58,000. Finally, C M Bidwell & Associates Ltd. boosted its holdings in Axonics by 108.2% in the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company's stock valued at $71,000 after purchasing an additional 660 shares during the period. Hedge funds and other institutional investors own 99.48% of the company's stock.

Axonics Stock Up 0.4 %

Shares of Axonics stock traded up $0.24 during mid-day trading on Monday, reaching $66.93. 656,211 shares of the stock traded hands, compared to its average volume of 1,242,642. The stock has a market capitalization of $3.41 billion, a PE ratio of -514.85 and a beta of 0.56. The business has a 50-day moving average of $67.90 and a 200 day moving average of $62.84. Axonics has a fifty-two week low of $47.59 and a fifty-two week high of $69.68.

Axonics (NASDAQ:AXNX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.06 by $0.07. Axonics had a negative return on equity of 1.00% and a negative net margin of 1.66%. The firm had revenue of $109.70 million during the quarter, compared to the consensus estimate of $107.33 million. During the same period in the prior year, the company earned $0.01 EPS. The firm's revenue was up 27.7% compared to the same quarter last year. On average, equities research analysts expect that Axonics will post 0.32 EPS for the current fiscal year.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.